American Journal of Cardiology
Volume 96, Issue 11 , Pages 1589-1604, 1 December 2005

The Editor’s Roundtable: Cyclooxygenase-2 Inhibitors and Cardiovascular Risk

  • Robert S. Bresalier, MD

      Affiliations

    • Professor and Chairman, Department of Gastrointestinal, Medicine and Nutrition, Birdie J and Lydia J Resoft Distinguished Professor in Gastrointestinal Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas
    • Dr. Bresalier is on the advisory board for Merck Research Laboratories, San Diego, California.
    • ,
  • Vincent E. Friedewald Jr, MD

      Affiliations

    • Visiting Professor and Director, New Media Center, University of Notre Dame, Notre, Dame, Indiana
    • Corresponding Author InformationCorresponding author: Tel: 574-631-7608; fax: 574-631-8209.
    • Drs. Friedewald, Rakel and Roberts have no relevant financial relationships to disclose.Conflicts of interest were resolved through peer review.
    • ,
  • Robert E. Rakel, MD

      Affiliations

    • Professor, Department of Family and Community Medicine, Baylor College of Medicine, Houston, Texas
    • Drs. Friedewald, Rakel and Roberts have no relevant financial relationships to disclose.Conflicts of interest were resolved through peer review.
    • ,
  • William C. Roberts, MD

      Affiliations

    • Medical Director, Baylor Heart and Vascular Institute, Baylor, University Medical Center, Dallas, Texas; Editor-in-Chief, The American Journal of Cardiology, and Dean, A. Webb Roberts Center for Continuing Medical Education of Baylor Health Care, System, Dallas, Texas
    • Drs. Friedewald, Rakel and Roberts have no relevant financial relationships to disclose.Conflicts of interest were resolved through peer review.
    • ,
  • Gary W. Williams, MD, PhD

      Affiliations

    • Chairman, Department of Medicine, Scripps Clinic, Medical Group; Vice President, Medicine Services and Academic Affairs Scripps Clinic Foundation, La Jolla, California.
    • Dr. Williams receives honoraria for speaking and consulting for Pfizer, Inc., New York, New York. He is on the advisory board and conducts research protocols for Pfizer.

Received 23 September 2005; accepted 23 September 2005. published online 24 October 2005.

No abstract is available. To read the body of this article, please view the Full Text online.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 This activity is supported by an educational grant from Pfizer, Inc., New York, New York.Disclosure

PII: S0002-9149(05)01620-6

doi:10.1016/j.amjcard.2005.09.069

American Journal of Cardiology
Volume 96, Issue 11 , Pages 1589-1604, 1 December 2005

Article Tools

* Image Usage & Resolution